Company Filing History:
1 out of 601 
1 out of 590 
Years Active: 2017
Title: Inventor Claire Mach: Pioneering Cancer Therapy Through MicroRNA Innovations
Introduction
Claire Mach, an accomplished inventor based in Houston, TX, has made significant strides in the field of cancer therapy. With her innovative research, she has developed a patented method that utilizes microRNAs to enhance the effectiveness of platinum-based chemotherapy treatments, particularly for ovarian cancer. Her contributions are a testament to the potential of microRNA technology in advancing medical treatments.
Latest Patents
Claire Mach holds one patent titled "miR-520 microRNAs sensitize cancers to platinum-based therapy." This groundbreaking invention focuses on methods and compositions that involve microRNAs or their variants administered to individuals for various medical treatments, aiming to sensitize cancers to therapy or to prevent cancers from becoming resistant to treatments. The patent specifically highlights the use of microRNAs including miR-520a (with variants miR-520a-3p and miR-520a-5p), miR-520g, and miR-520h, particularly in relation to ovarian cancer and platinum-based chemotherapy.
Career Highlights
Claire Mach has built an impressive career, with key roles at prominent institutions such as Baylor College of Medicine and the University of Houston System. Her work has consistently focused on harnessing microRNA technology to improve cancer treatments, showcasing her dedication to innovative medical research.
Collaborations
Throughout her career, Claire has collaborated with notable colleagues, including Matthew L. Anderson and Preethi Gunaratne. These partnerships have enriched her research endeavors, allowing for a multidisciplinary approach to developing novel cancer therapies.
Conclusion
In summary, Claire Mach's innovative approach to utilizing microRNAs in cancer treatment represents a significant advancement in oncology. Her patent for enhancing the efficacy of platinum-based therapies is a crucial step towards improving patient outcomes in ovarian cancer and beyond. As researchers like Claire continue to push the boundaries of medical science, the future of cancer therapy looks increasingly hopeful.